Drug Discovery

#AI / data analytics / healthtech / informatics #Drug discovery

DDW exclusive: 2022 drug discovery challenges and opportunities 

DDW’s Megan Thomas spoke to key decision-makers from the drug discovery industry about their predictions on what 2022 holds for our sector, which can be downloaded and viewed for free from the DDW App for users of Apple or Android devices. “Carefully distinguishing true opportunities from passing fads will… Read More

#News #Trending News

Boston
#Comment #Drug discovery #Drug innovation #Lab automation #SLAS2022

From the editor: Being part of the innovation 

The Winter issue of the Drug Discovery World Magazine is accompanied by an exclusive DDW & SLAS2022 supplement ahead of SLAS2022 in Boston, US on 5-9 February. DDW Editor in Chief Lu Rahman comments.  There is huge excitement within the DDW team regarding the SLAS2022 International Conference and Exhibition in Boston on 5-9… Read More

#Editor's Choice #Exclusive Content #News

Artificial Intelligence
#AI / data analytics / healthtech / informatics #Collaboration #Drug discovery

BenevolentAI announces collaboration with AstraZeneca 

BenevolentAI, a clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership.   The expansion  The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and… Read More

#News

#Antibiotics #Drug development #Funding #Research

US researcher awarded $3.6 million to study antibiotic resistance

Sanford Burnham Prebys professor Andrei Osterman, Ph.D., has been awarded a $3.6 million grant from the National Institutes of Health (NIH) to expand current knowledge of antibiotic resistance, which will inform more precise antibiotic prescribing practices and help researchers develop drugs that are harder for bacteria to resist.   Context… Read More

#News

#Drug discovery #Pharmaceuticals

Pharmaceutical executive takes the Synature Discovery reins 

Sygnature Discovery, providers of drug discovery solutions, has appointed Dr Charles Woler as Chairman.  Woler’s career Dr Woler has held multiple key roles in the sector, including CEO at Roche France, Executive Chairman for Europe at SmithKline Beecham, and CEO at Cadus Pharmaceutical in the US.   Official comments … Read More

#News #Trending News

#Comment #Covid-19 #Drug development #Drug discovery

From the editor: Courage and curiosity in collaboration 

Collaboration within the drug discovery sector is well documented, says Lu Rahman. During the Covid-19 pandemic we have seen great examples. Take Pfizer and BioNTech or the work between Carterra and Eli Lilly Company to create bamlanivimab, a Covid-19 therapeutic. Collaborative work has created vaccines and therapeutics which are… Read More

#Editor's Choice #News #Opinion

#Drug discovery #Drug targets #Drug technology #Pharmaceuticals #Quantum computing

How quantum computing can benefit drug discovery 

Listen to this article on the DDW Podcast: Brad Loren, Matthew Marrone, and Christopher Singer, of intellectual property and technology law firm McAndrews, Held & Malloy, on quantum computing and its benefits to drug discovery.  Explaining quantum computing and its promise  Before we… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Cancer research #Clinical trials #Drug development #Molecular research #Oncology #Personalised medicine

Exclusive: The personalised medicine paradigm

Since the turn of the century, when the term “personalised medicine” was first coined, the use of molecular diagnostic (or biomarker) testing in clinical trials has continued to grow in terms of complexity and importance. These tests have undergone a period of rapid development and growth in the last decade, with the implementation… Read More

#Editor's Choice #Exclusive Content #News

#AI #Collaboration #Drug development #Drug discovery

Exscientia and Sanofi to develop AI-driven medicines 

Sanofi and Exscientia have announced a research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilising actual patient samples.   Background  The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small… Read More

#News

#Collaboration #Drug development #Immunology / Virology & Vaccines #mRNA

Pfizer and BioNTech develop first mRNA-based shingles vaccine

Pfizer and BioNTech have announced a new research, development and commercialisation collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), which impacts about one in three people in the US during their lifetime.   Why now?  The collaboration… Read More

#News

#Drug development #Partnership

Quebecian acquisition expands preclinical platform 

Altasciences, an integrated CRO/CDMO offering solutions to early-stage drug development, has completed the acquisition of Sinclair Research, a preclinical CRO located in the Midwest (US). The new site will facilitate access to Altasciences’ preclinical services across the US.  “This acquisition will add significant capacity and expertise to Altasciences’ existing… Read More

#News

#AI / data analytics / healthtech / informatics #Biotechnology #Database #Drug development #R&D #Research

Bridging the gap between R&D teams in biotechnology   

Ashu Singhal, President & Co-Founder of Benchling, shares newly heightened expectations for the biotechnology industry following the developments of the last 18 months.   The last 18 months have heightened expectations for the biotechnology industry. Scientists came together to develop vaccines at record speeds and set the… Read More

#News

#CRISPR #Drug discovery #Precision medicine #Therapeutics

Therapeutics: Changing the way we treat disease – podcast 

The latest free-to-listen DDW podcast episode is titled “Therapeutics: Changing the way we treat disease”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine and has been narrated by DDW’s Megan Thomas.  These articles are titled: “Avoiding double strand breaks on… Read More

#News

#Biosciences #Cancer research #Drug development #Drug discovery #Oncology #Precision medicine

Anticancer Bioscience expands to Chinese biotech research park 

Anticancer Bioscience, a company developing synthetic lethal approaches to precision oncology, have relocated to Tianfu International Biotown, in Chengdu, China, to accommodate its growth and expansion, and on the back of its recent financing. Biotown is considered the premier biotech research park in Chengdu, the capital of Sichuan province.  The… Read More

#News

Artificial Intelligence
#AI / data analytics / healthtech / informatics #Biotechnology #Drug discovery #Drug targets

Collaboration to use AI for drug design and retrosyntheis 

The Drug Discovery Unit (DDU) in the School of Life Sciences at The University of Dundee is using Iktos’ generative modelling artificial intelligence (AI) technology in one of its drug discovery programmes.  The collaboration   Iktos will apply its de novo ligand and structure-based generative modelling technologies, its AI-based… Read More

#News

#Drug discovery #Genetic editing #Hit identification #Medicinal chemistry #Podcast

Using biotechnology to maximise drug discovery output – podcast 

The latest free-to-listen DDW podcast episode is titled “Using biotechnology to maximise drug discovery output”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine and has been narrated by DDW’s Megan Thomas.  These articles are titled: “The important integration of medicinal chemistry in Hit-to-Lead… Read More

#News